<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04615611</url>
  </required_header>
  <id_info>
    <org_study_id>SAL-POWER</org_study_id>
    <nct_id>NCT04615611</nct_id>
  </id_info>
  <brief_title>Physiologic Performance Response to Salbutamol</brief_title>
  <official_title>Individual beta2-adrenergic Performance Response to Salbutamol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project aims to investigate the individual physiological response to beta2-adrenergic&#xD;
      stimulation with salbutamol on performance-related outcomes&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 7, 2020</start_date>
  <completion_date type="Anticipated">November 7, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 7, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sprint performance</measure>
    <time_frame>Measured ½ hour after drug administration</time_frame>
    <description>Power output during maximal cycling</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle strength</measure>
    <time_frame>Measured ½ hour after drug administration</time_frame>
    <description>Quadriceps maximal voluntary contraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sprint fatigue tolerance</measure>
    <time_frame>Measured ½ hour after drug administration</time_frame>
    <description>Fatigue index during maximal cycling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cycling endurance performance</measure>
    <time_frame>Measured ½ hour after drug administration</time_frame>
    <description>4-min time trial on bike ergometer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>salbutamol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>salbutamol, 800 microgram from metered dose inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>salbutamol</intervention_name>
    <description>inhalation of salbutamol</description>
    <arm_group_label>salbutamol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>administration of placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 to 45 years of age&#xD;
&#xD;
          -  Trained individuals with maximal oxygen uptake above 55 mL/kg/min for men and 50&#xD;
             mL/kg/min for women&#xD;
&#xD;
          -  Body mass index lower than 26&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy towards study drug&#xD;
&#xD;
          -  Unacceptable side effects of the study drug&#xD;
&#xD;
          -  Chronic disease deemed by the MD to impose a risk or severely confound the study&#xD;
             outcomes&#xD;
&#xD;
          -  Current smokers&#xD;
&#xD;
          -  Use of prescription medicine&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 29, 2020</study_first_submitted>
  <study_first_submitted_qc>October 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2020</study_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Morten Hostrup, PhD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

